2Shima Y, Mihara R, Suzuki M, et al. Pharmacokinetic studies of AY4166 ( I ) - absorption, distribution and excretion in rates after single adminis- triation [ J ]. Jpn Pharmaeol Ther, 1997, 25 (Suppl) : 181 - 193.
4Kaleemuddin M, Srinivas P. Lyophilized Oral Sustained Release Polymeric Nanoparticles of Nateglinide[J]. AAPS Pharm Sci Tech, 2013,14 (1): 78 - 85.
5Vaghani SS, Patel MM, Satish CS, et al. Synthesis and characterization of carboxymethyl chitosan hydrogel : application as pH - sensitivedelivery for nateglinide [ J ]. Curr Drug Deliv ,2012,9 (6) :628 - 636.
6Hu S,Wang S,Fanelli B,et al. Pancereatic beta-cell K (ATP)channel activity and membrance-binding studies with nateglinide:a comparison with salfonylureas and repaglinide [J]. J Pharmacol Exp Ther,2000,293(2):444- 452.
8Grunberger G. Quo vadis nateglinide? Ten-year perspec- tive [J]. Expert Opin Pharmacother, 2011,12 (13) : 2097- 2106.
9Abdelmoneim AS, Hasenbank SE, Seubert JM, et al. Varia- tions in tissue selectivity amongst insulin secretagogues:a systematic review [J]. Diabetes Obes Metab,2012,14(2): 130-138.
10Group NS, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascu- lar events [J]. New Engl J Meal,2010,362(16) : 1463-1476.
